Briacell Therapeutics Corp BCTX

$3.19 +0.18 (5.98%)

Valuation

Market cap
26,284,000
Revenue TTM
$0
Net income TTM
$-26,310,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
63,400
Avg volume
116,556
Day's range
$3.02 – $3.27
Shares out
8,732,000
Stochastic %K
33%
Beta
1.26
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

SmallCapGrowth Nov 5, 2:51 PM
MOMO'S BREAKOUT BOARD: $BCTX’s Bria-IMT™ named 2026 Immu... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=178108197 via @Investors_Hub
0 replies
2maligators Nov 5, 2:43 PM
$BCTX like seriously..to get that award and still be at $3. We’re not even a pump and dump anymore just dump 💩
1 replies
CoffeeRocks Nov 5, 2:42 PM
$BCTX 3$-3.3$S are a BuY
0 replies
SmallCapGrowth Nov 5, 2:32 PM
$BCTX ’s Bria-IMT™ named 2026 Immunotherapy Solution of the Year demonstrating median survival of 13.3-16.6 months in Phase 2 studies versus historical benchmarks of 5.9-9.8 months. Clinical validation + Phase 3 catalyst = one to watch. #Biotech NEWS: https://bit.ly/4Ad0M12
0 replies
SmallCapGrowth Nov 5, 2:28 PM
$BCTX just earned BioTech Breakthrough’s 2026 “Immunotherapy Solution of the Year” award for Bria-IMT™, further validating its novel approach to metastatic breast cancer treatment. Pivotal Phase 3 study underway, momentum builds #Biotech #CancerCare NEWS:https://bit.ly/4Ad0M12
0 replies
AliceFireSteam Nov 5, 2:10 PM
$BCTX very bullish! Adding more as soon as possible!!
0 replies
SmallCapVoice Nov 5, 1:39 PM
BriaCell ($BCTX) has been named BioTech Breakthrough’s 2026 “Immunotherapy Solution of the Year” as its lead candidate, Bria-IMT, advances through a pivotal Phase 3 study for metastatic breast cancer. Phase 2 median survival reached 13.3–16.6 months vs. historical benchmarks of 5.9–9.8 months. Read the full PR: https://www.globenewswire.com/news-release/2026/11/05/3396403/0/en/briacell-awarded-2026-immunotherapy-solution-of-the-year-by-biotech-breakthrough.html
0 replies
smallpower17 Nov 5, 1:21 PM
$BCTX HUGE! https://feeds.issuerdirect.com/news-release.html?newsid=8385780033190958&symbol=BCTX
1 replies